<DOC>
	<DOCNO>NCT01658462</DOCNO>
	<brief_summary>National , randomize , unblinded , phase IIb trial 2 stratum : First-line chemotherapy / Second-line chemotherapy locally recurrent metastatic breast cancer .</brief_summary>
	<brief_title>Phase II Study Docetaxel +/- Nintedanib Breast Cancer</brief_title>
	<detailed_description>Patients stratify randomization accord first-line chemotherapy / Second-line chemotherapy metastatic locally recurrent breast cancer Treatment progression unacceptable toxicity Visits plan every 3 week treatment every 3 month end treatment patient 's withdrawal</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Nintedanib</mesh_term>
	<criteria>Age ≥ 18 year old Histologically cytologically confirm adenocarcinoma breast Locally recurrent metastatic disease HER 2 negative status Requiring first secondline chemotherapy locally recurrent metastatic disease . Prior first line chemotherapy contain Docetaxel Measurable evaluable disease accord RECIST 1.1 criterion Allowed prior chemotherapy follow : Docetaxel neoadjuvant adjuvant setting allow provide relapse observe 12 month end docetaxel treatment Bevacizumab 1st line allow washout 4 week , recovery NCICTCAE v3.0 toxicity ECOG performance status 01 Adequate bone marrow , hepatic renal function evidence follow : Hemoglobin ≥ 10 G/100 mL Neutrophils count ≥ 1500 /mm3 Platelets ≥ 100 000 /mm3 Total bilirubin ≤ ULN ( ULN : Upper Limit Normal ) SGOT/SGPT ≤ 1.5 x ULN ( ≤ 2.5 x ULN case hepatic metastasis ) Serum alkaline phosphatase ≤ 2.5 x ULN Creatinin clearance ≥ 45 ml/min creatinin ≤ 1.5 x ULN Proteinuria &lt; CTCAE grade 2 Coagulation parameter : International normalise ratio ( INR ) ≤ 2 , prothrombin time ( PT ) partial thromboplastin time ( PTT ) ≤ 50 % deviation institutional ULN Effective contraception patient ( male female ) reproductive potential entire participation study 3 month last administration Nintedanib Docetaxel Negative pregnancy test ( serum betaHCG ) perform within 1 week prior start study treatment female reproductive potential Patient cover government health insurance Signed date write informed consent prior admission study accordance ICHGCP guideline local legislation Concomitant hormone therapy metastatic breast cancer Patients dysphagia , inability swallow tablets Other serious illness medical condition : Cardiac disease Unstable diabetes Uncontrolled hypercalcemia Pregnancy breast feed woman Unable medical followup ( geographic , social mental reason ) Prior treatment Nintedanib VEGFR inhibitor Known hypersensitivity trial drug , excipients , peanut , soya contrast medium Contra indication use backbone treatment comparator Active brain metastasis ( e.g . stable &lt; 4 week , adequate previous treatment radiotherapy , symptomatic , require treatment anticonvulsant ; dexamethasone therapy allow administer stable dose least one month randomisation ) Leptomeningeal disease Radiographic evidence cavitary necrotic tumor Centrally locate tumor radiographic evidence ( CT MRI ) local invasion major blood vessel History clinically significant haemorrhagic thromboembolic event past 6 month Known inherited predisposition bleed thrombosis Significant cardiovascular disease ( i.e . uncontrolled hypertension , unstable angina , history infarction within past 12 month prior start study treatment , congestive heart failure &gt; NYHA II , serious cardiac arrhythmia , pericardial effusion ) Other malignancy within past 5 year basal cell skin cancer carcinoma situ cervix Active serious infection particular require systemic antibiotic antimicrobial therapy Active chronic hepatitis C and/or B infection Active alcohol drug abuse Significant weight loss ( &gt; 10 % BW ) within past 6 month prior inclusion trial</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>locally recurrent metastatic breast cancer</keyword>
	<keyword>Docetaxel</keyword>
	<keyword>Nintedanib</keyword>
</DOC>